Clinical Oncology Next-generation Sequencing Market

Clinical Oncology Next-generation Sequencing Market Outlook from 2024 to 2034

The clinical oncology next-generation sequencing market size stands at USD 635 million in 2024. The clinical oncology NGS market size is set to rise at a 17.3% CAGR through 2034. Revenues are expected to surpass USD 3,131.5 million by 2034.

Cancer has significant ramifications for global economic frameworks. In the United States alone, an estimated 2,000,140 new cancer cases are anticipated solely in 2024. Projections from experts suggest that the number of cancer survivors could surpass 22.5 million by 2032.

The global healthcare sector necessitates advancements in diagnostic modalities and therapeutic technology innovations. This is necessary to augment patient outcome efficacies correlating with ascending global cancer case incidences.

Clinical oncology NGS serves such requisites by rendering pivotal insight regarding molecular mechanisms instigating cancer initiation and evolutionary dynamics. By characterizing genomic alterations that initiate tumorigenesis, NGS enables the identification of appropriate interventions like targeted therapies. It aids in formulating individualized therapeutic frameworks for patients based on specific tumoral somatic or genetic profiling details.

The cost of clinical oncology NGS has decreased suggestively over the years. Whole genomes can be sequenced for less than USD 1,000 now. This has been possible due to technological advances, economies of scale, and competition among various sequencing service providers. As the cost of sequencing decreases, it becomes more economically competitive for clinical laboratories and medical institutions.

Decreasing costs have made the technology accessible to many people. Patients can now undergo genomic profiling through personalized cancer treatments. Lower sequencing costs have led to more research efforts and cancer screening in the general population. Therefore, leading to further growth and breakthroughs in the field of oncology.

Attributes	Description
Expected Global Clinical Oncology Next-generation Sequencing Market Size (2024E)	USD 635 million
Projected Global Clinical Oncology Next-generation Sequencing Market Value (2034F)	USD 3,131.5 million
Value-based CAGR (2024 to 2034)	17.3%

Key Industry Highlights

Liquid Biopsy Technology Makes Advances in the Industry

One of the most revolutionary solutions in terms of cancer diagnostics and monitoring is liquid biopsies. Clinical oncology NGS technologies undoubtedly play a central role in liquid biopsies. They involve analyzing circulating tumor DNA or other biomarkers from blood or bodily fluids. It means that tumor dynamics and responses to treatment can be tracked in a minimally invasive manner.

As NGS technologies can detect genetic mutations in ctDNA with high sensitivity, they help better understand tumor heterogeneity and evolution on a regular basis. For this reason, the non-invasive nature of liquid biopsies opens uniquely new perspectives for cancer patient care. It can help detect tumor recurrence early and adjust treatment dynamically, which enhances patient outcomes significantly.

In February 2024, Twist Bioscience Corporation launched the cfDNA Library Preparation Kit to enable liquid biopsy research. It is designed to maximize the number of unique cfDNA molecules captured in library preparation.

Development of New Approaches Creates Opportunities in the Industry

The contributions to innovations in clinical oncology NGS by the investment in research and development have been steady and prolific. This has led to the introduction of new sequencing platforms that are considered revolutionary.

Advanced bioinformatics tools and non-traditional applications in the field of oncology continue to appear in the clinical oncology next-generation sequencing market. Key areas driving research include performance, throughput, and scalability, which has led to the clinical use of NGS technologies. Their utility is addressing challenges like data analysis plus interpretation.

Partnerships among academic institutions, industry partners, and government agencies have highly expedited efforts in NGS-based cancer research. In July 2023, a group of researchers from the Perelman School of Medicine at the University of Pennsylvania developed a new approach to mapping specific DNA marks known as 5-methylcytosine (5mC).

These marks play a regulatory role in gene expression and are pivotal in health and disease. This ground-breaking technique enables scientists to create a profile of DNA using minuscule samples that are virtually non-damageable. This new approach named Direct Methylation Sequencing (DM-Seq) has opened doors of opportunities of players.

Artificial Intelligence is Making Inroads in the Industry

Integration of artificial intelligence in NGS data analysis for cancer research continues to rise in the industry. Increasingly sophisticated artificial intelligence and machine learning algorithms allow geneticists to gain deeper insights into NGS data. They help improve the accuracy and precision of variant calling, annotation, and interpretation.

This allows the detection of medically relevant mutations and the prediction of therapeutic responses based on underlying molecular biology. They help in the identification of patient populations for tailored treatment selection/assignment.

The integration of these AI algorithms into NGS workflows can increase the level of clinical efficacy of NGS assays and empower precision oncology initiatives in general. These technologies are, therefore, witnessing more integration in the industry.

In September 2023, QIAGEN expanded its clinical decision support software to include AI-enhanced coverage of thousands of rare disease genes. Advancement of somatic NGS testing with QCI interpretation for oncology can lead to streamlined filtering of structural variants.

2019 to 2023 Clinical Oncology Next-generation Sequencing Sales Outlook Compared to Demand Forecast for 2024 to 2034

The market size for clinical oncology NGS sequencing expanded at a 19% CAGR between 2019 and 2023. The industry has witnessed a surge in the adoption of long-read sequencing technologies. These include PacBio sequencing and Oxford Nanopore sequencing, for both research and clinical applications in oncology.

Complex genomic rearrangements and repeat sequences are difficult to resolve by short-read sequencing technologies. The emergence of long-read sequencing has greatly expanded the toolbox for oncologists who need to understand tumor biology, including genomic instability.

The rising cases of cancer create a positive outlook for the clinical oncology next-generation sequencing market. The clinical oncology NGS market forecast estimates expansion at a 17.3% CAGR until 2034. More sophisticated bioinformatics tools and analysis algorithms will be developed to address the complexity and quantity of NGS data.

The application of AI and machine learning paradigms in next-generation sequencing data analysis pipelines will become more prevalent. They will help to improve genomic variant calling, annotation, and interpretation. This can enable more confident treatment recommendations and improve the clinical utility of NGS-based assays.

Country-wise Insights

This section covers the future forecast of the clinical oncology next-generation sequencing industry in the top three countries. Information on regions like North America, Europe, Asia Pacific, and others is granulated, focusing on the top countries.

France is anticipated to be at the forefront with a 21.6% CAGR through 2034. The United States follows next at a 19.4% CAGR projected through 2034. Germany secures third place, expanding at a 19.2% CAGR through 2034. Analysis indicates that Europe is likely to be the most revenue generation region for the coming decade.

Countries	CAGR 2024 to 2034
France	21.6%
United States	19.4%
Germany	19.1%

Government Funding and Initiatives Foster Growth in France

The clinical oncology next-generation sequencing market expansion in France is anticipated at 21.6% through 2034. In France, a network of Next Generation Sequencing (NGS) interests is aligning to drive the technology forward in oncology research and clinical practice. This includes government initiatives and very generous funding programs, such as the National Cancer Institute and Investments for the Future.

There is a robust academic research infrastructure and premier research institutions for biomedical research. These include the Curie Institute and the Gustave Roussy Cancer Center, which are renowned for genomic and cancer biology innovation and excellence. Demand is growing for NGS-based genetic testing in rare and familial cancers, helping the industry thrive in France.

Rising Demand for Liquid Biopsy Supports Expansion in the United States

The clinical oncology next-generation sequencing market in the United States is anticipated to rise at a 19.4% CAGR through 2034. Initiatives such as ORIEN and NCI MATCH support genomic research studies and the recruitment of participants for trials. Currently, genetic testing services offered directly to consumers are raising awareness among the public and creating a demand for NGS-based oncology testing.

FDA initiatives like the Breakthrough Devices Program speed up the introduction of assays into the industry. Also, linking with Electronic Health Records (EHRs) improves decision-making support and patient care. This diverse landscape establishes the United States as a runner in clinical oncology NGS. The country is promoting progress in precision medicine and research on genomic-driven oncology.

Greater Emphasis on Diagnosing and Treating Diseases Spurs Adoption in Germany

The clinical oncology next-generation sequencing market in Germany is expected to rise at a 19.1% CAGR through 2034. The robust healthcare system emphasizes diagnosing and treating diseases. This emphasis has led to an increase in the use of clinical oncology NGS technology in clinical genetics and cancer care.

Specialized centers and genetic testing programs provide NGS-based testing and counseling services, leading to a higher interest in precision medicine. Additionally, strict standardization and quality assurance measures ensure the precision and dependability of NGS results. This helps in building trust among healthcare professionals and patients. This holistic approach highlights Germany’s dedication to delivering top-notch healthcare services.

Category-wise Insights

This section takes a closer look at the market segmentation of clinical oncology next-generation sequencing. The research indicates that the kits and reagents segment under components is dominating. The segment captured 60.9% of shares in 2024. Under technology, the synthesis sequencing (SBS) segment holds the leading shares at 68.5% in 2024.

Kits and Reagents are Leading Components

Segment	Kits and Reagents (Components)
Value Share (2024)	60.9%

The increased adoption of NGS technology in clinical oncology fuels demand for consumables like kits and reagents. As NGS applications expand to tumor profiling, liquid biopsy analysis, and companion diagnostics, specialized consumables tailored to each assay's needs are required.

Customization of assays and technological advancements lead to the development of new, high-performance consumables. Automation and high-throughput solutions streamline workflows. With the rising volume of research and clinical testing, the demand for consumables continues to grow. This rise reflects the integral role kits and reagents play in NGS-based oncology testing and research.

Synthesis Sequencing is the Leading Technology

Segment	Synthesis Sequencing (Technology)
Value Share (2024)	68.5%

Synthesis sequencing's surge as the leading technology in the clinical oncology NGS market stems from its compelling attributes. Offering rapid analysis, cost-effectiveness, scalability, and flexibility, it meets the urgent needs of oncology diagnostics.

Its reduced sample input requirements and simplified workflows accommodate diverse clinical samples and streamline laboratory operations. Moreover, recent advancements in accuracy and read lengths enhance its clinical relevance and utility. These factors collectively propel the demand for synthesis sequencing.

Competition Outlook

The clinical oncology next-generation sequencing (NGS) market is highly competitive, fueled by technology improvements, strategic alliances, and regulatory changes.

Established industry leaders include Illumina, Thermo Fisher Scientific, and Qiagen, while disruptive firms like Pacific Biosciences and Oxford Nanopore offer novel solutions. The environment is shaped by strategic partnerships, mergers and acquisitions, as well as regulatory clearances and reimbursement rules.

Industry Updates

• In April 2024, the FDA approved tisotumab vedotin-tftv by Tivdak, Seagen Inc. (now a part of Pfizer Inc.), for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.
• In April 2024, the FDA approved alectinib by Alecensa, Genentech Inc., for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.

Leading Clinical Oncology Next-generation Sequencing Brands

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies Ltd.
• Agilent Technologies, Inc.
• BGI Group
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.

Key Segments of Market Report

By Component:

Based on component, the industry fragments into sequencing platforms, sequencing products, kits and reagents, and services.

By Technology:

Depending on technology, the sector is segmented into ion semiconductor sequencing, pyro-sequencing, synthesis sequencing (SBS), real time sequencing (SMRT), ligation sequencing, reversible dye termination sequencing, and Nano-pore sequencing.

By Application:

Clinical oncology next-generation sequencing finds application in whole tumor genome sequencing, whole tumor exome sequencing, targeted tumor genome profiling, tumor transcriptome sequencing, tumor-normal comparisons, and others.

By End User:

Top end user existing in this industry are hospitals, laboratories, clinical research organizations, diagnostic laboratories, and others.

By Region:

Analysis of the market has been conducted in the countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, and Middle East & Africa (MEA).

Frequently Asked Questions

How Big is the Clinical Oncology NGS Market?

Industry is set to reach USD 635 million in 2024.

What is the Sales Forecast through 2034?

The industry is expected to reach USD 3,131.5 million by 2034.

What is the Potential CAGR of the Clinical Oncology Next-generation Sequencing Market?

Industry is set to report a CAGR of 17.3% from 2024 to 2034.

Which is the Leading Clinical Oncology NGS Component?

Kits and reagents lead the industry, with a share of 60.9% for 2024.

How will the Industry in France Progress?

The market in France is expected to advance at a CAGR of 21.6% through 2034.